Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PA9159 Nasal Spray in Healthy Chinese Adults
NCT05170763Phase 1Completed
- Sponsor
- Anhui Palo Alto Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pa9159 in allergic rhinitis (AR) (6 arms), sponsored by Anhui Palo Alto Pharmaceuticals. Primary endpoints: Number of subjects experiencing adverse events, Number of subjects having abnormal hematology laboratory parameters and 10 more. Started Nov 2021; status: completed.
02
Drugs
pa9159
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT05170763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170763.